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Abstract: Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI,
DSC-MRI methodology has not been standardized, hindering its utilization for
response assessment in multi-center trials. Recently, the DSC-MRI Standardization
Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an
updated consensus DSC-MRI protocol compatible with BTIP, the standardized brain
tumor imaging protocol for high-grade gliomas that is increasingly used in the clinical
setting and is the default MRI protocol for the National Clinical Trials Network. After
reviewing the basis for controversy over DSC-MRI protocols, this manuscript provides
evidence-based best practices for clinical DSC-MRI as determined by the Committee,
including pulse sequence (gradient echo vs. spin echo), BTIP-compliant contrast agent
dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing
leakage correction. In summary, full-dose preload, full-dose bolus dosing using
intermediate (60°) FA and field strength-dependent TE (40-50ms at 1.5T, 20-35ms at
3T) provides overall best accuracy and precision for cerebral blood volume estimates.
When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing
using low FA (30°) and field strength-dependent TE provides excellent performance,
with reduced contrast agent usage and elimination of potential systematic errors
introduced by variations in preload dose and incubation time.
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On behalf of my co-authors, I wish to thank you and the reviewers for the conditional 
acceptance of manuscript N-O-D-20-00183.  We found the reviewer’s comments and 
suggestions to be substantive and constructive and are thankful to have been given the 
opportunity to strengthen our manuscript.  I am resubmitting our revised manuscript N-O-D-
20-00183R1, which is again entitled: “Consensus Recommendations for a Dynamic 
Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.”  There have been no 
changes to the title or author list.  Please note that no figures or tables are copied directly 
from another source. 
Our point-by-point response to each reviewer’s comments can be found in the uploaded 
Response to Reviewer’s Comments document.  Common themes to the reviewer’s 
comments included inquiry about more specific recommendations for post-processing of the 
DSC-MRI data, including leakage correction. We feel that we addressed these questions 
and comments to the best of our ability and hope that you and the reviewers find our 
responses to be satisfactory. 
I wish to again thank you for consideration of our manuscript.  Please do not hesitate to 






Jerrold L. Boxerman, M.D., Ph.D., F.A.C.R. 
Cover Letter
Response to reviewer’s comments 
 
Reviewer 1  
These consensus recommendations are a great step forwards in brain tumor 
imaging, since results between different institutions remain incomparable until a 
standardization is lacking. 
 
There is only one point to consider in the paragraph "Variability of DSC-MRI 
Methodology in the Literature". Authors discuss the heterogeneity of the results, 
with a special attention on the threshold values of rCBV to assess treatment 
response. There is always a residual clinical uncertainty, since even the gold 
standard of histopathological diagnosis has its weaknesses and most studies are 
based mainly on clinical course parameters.  
 
The reviewer raises an excellent point: gold standards for histology and clinical 
outcomes are difficult to come by. We included this section in the manuscript to 
provide an example of how literature results regarding the use of CBV for 
distinguishing true progression from pseudoprogression can appear to lack 
consistency. It is true that the methodologies and gold standards used for the 
establishment of these thresholds differ from site to site, but the point is that 
differences in acquisition protocol are suspected to greatly impact clinical 
interpretation, thereby motivating our establishment of a consensus DSC-MRI 
protocol. The DRO work by Quarles et al that we cite in the same section of our 
manuscript emphasizes this point, since the DRO-based simulations eliminate 
issues regarding gold standard histopathological diagnosis and isolate the 
ambiguity in threshold determination due to heterogeneity of acquisition and 
post-processing methodology. 
 
Authors should consider another very important issue before officially making 
recommendations: The critical ROI selection. Most of the DSC perfusion studies 
found that the use of maximum rCBV instead of the mean has fundamental 
impact on diagnostic value of the method. The best measure to establish 
diagnostic threshold values is the relative rCBV value, related to the anatomically 
mirrored normal appearing tissue region of the contralateral hemisphere. In 
addition, it should be avoided to integrate vessels in the measuring ROI. For this 
purpose, post-processing tools providing a co-registered underlay of the contrast-
enhanced T1-w image is crucial to measure the rCBV. Strictly speaking, these 
points are not part of the sequence parameters (MR protocol), but they are a very 
important part of post-processing and thus for the diagnostic accuracy. 
 
We thank the reviewer for raising these excellent points. ROI selection is critical, 
and clinical results will indeed differ depending on whether mean or maximum 
CBV is used, and whether relative or standardized CBV maps are interpreted. 
However, the primary focus of this manuscript is the DSC-MRI acquisition 
protocol (i.e., particulars of the DSC-MRI CBV map generation process), 
including contrast agent dosing, MRI acquisition parameters, and post-
processing of the DSC-MRI signal. We have therefore purposefully avoided 
Response to Reviewers
discussion of CBV analysis tools and methodologies. These are very important 
issues and would merit their own consensus recommendations. We believe that 
a crucial first step for the universal applicability of DSC-MRI is unification of the 
acquisition protocol, which we hope to have achieved with this manuscript. In 
theory, if DSC-MRI data are collected in a standardized way in multi-center 
clinical trials, then we can compare multiple post-processing and lesion selection 
methodologies in the future.  
 
It may very well be the case that it will take acceptance of a single CBV analysis 
software implementation by the neuro-oncology community for widespread use 
with reproducible results to be achieved, similar to the acceptance of 
IschemaView RAPID software for thrombectomy trials by the interventional 
neuroradiology community. This is suggested by results from Bell et al. 
(Tomography. 2019 Mar;5(1):110-117; Ref. [63] in our manuscript) that 
demonstrated marked inter-site disagreement in computed rCBV when site-
specific software from 12 sites was applied to a common set of DSC-MRI source 
data. Issues related to CBV map generation and analysis are complex and are 
being actively explored and will require a separate consensus paper. 
 
Reviewer 2  
Excellent review of theory and literature to justify consensus DSC MRI 
recommendations. Minor suggestions below: 
 
Page 9- do the authors mean "regimes" or "regimens" ?  
 
The reviewer raises an excellent question, since “regime” is often confused with 
“regimen.”  In this case, we do believe that “regime” is appropriate. According to 
Google Dictionary, definitions include “the conditions under which a scientific or 
industrial process occurs,” and we are using “limited regimes” to describe the few 
sets of physiological and experimental conditions for which the MR signal loss 
due to susceptibility contrast can be described analytically. 
 
Page 11- perhaps request permission to reprint Fig 5 of Ref. [42] 
 
We thank the reviewer for this suggestion. We made a very strong effort to abide 
by the limitation of 7 total figures and tables for review articles in this Journal. We 
believe that the figures and tables that we have selected are integral to the 
manuscript. In fact, we have already relegated the tables summarizing the 
consensus protocol to supplementary material. Although in principle Fig. 5 of Ref. 
[42] would help illustrate the point being made in the “Consequences of Contrast 
Agent Extravasation” section on page 11, it is probably not crucial for the 
reader’s understanding of our point. In fact, our reference to Fig. 1 in Ref. [36] in 
the “Basic Contrast Mechanism for DSC-MRI” on page 9 is probably more 
germane to an appreciation of the fundamentals of susceptibility contrast. We are 
inclined to keep the number of figures within the recommended guidelines but 
are happy to add supplemental material should the editor deem it necessary.   
 
Page 12- good discussion of ferumoxytol. Suggest explicitly adding that this is 
not widely available.  
 
The reviewer makes a good suggestion, and we have added the following 
sentence to the ferumoxytol section on page 12: 
 
“FDA-approved as a therapeutic iron supplement, ferumoxytol is less commonly 
available than GBCA for MRI.” 
 
Suggest authors consider including a European author to add EU consensus or 
adoption. Someone like Marion Smits or similar?  
 
This is an excellent suggestion. We agree that “buy in” from the European 
community is important, and our author list already includes Marion Smits 
(representative of the EORTC), as well as neuro-oncologists from Heidelberg, 
Zurich, and Rotterdam.  We also have author representatives from the ABTC, 
ECOG-ACRIN, Alliance for Clinical Trials in Oncology, and the RTOG, and 
therefore feel that we stand a very good chance of achieving widespread 
compliance with our consensus protocol in the US and Europe.  
 
Although vendors will always have proprietary software, any suggestions to them 
to implement standard postprocessing steps as outlined in manuscript?  
 
This is an excellent point raised by the reviewer. Post-processing is very 
important and impactful for accurate CBV measurements but can be done in 
many different ways. Variations in post-processing methodology can introduce 
substantial variability in measured CBV, as demonstrated in Ref. [63]. We believe 
that it is safe to say that the BSW leakage correction scheme has, by far, the 
most clinical evidence to support its utility. Furthermore, the DRO work done by 
Quarles et al. (Ref. [66]) evaluated uncorrected and corrected DSC-MRI data and 
found that the BSW provided the highest accuracy. For these reasons, we are 
comfortable suggesting that at this point in time, the BSW method is an advisable 
technique for performing post-processing model-based leakage correction.  
 
However, implementation matters; different vendor implementations of the BSW 
leakage correction methodology can yield different CBV estimates for the same 
input data (Ref. [62]). We are obviously not in a position to provide explicit 
computer code for performing BSW. As we state in our reply to Reviewer #1, it 
may very well be the case that it will take acceptance of a single CBV analysis 
software implementation by the neuro-oncology community for widespread use 
with reproducible results to be achieved, similar to the acceptance of 
IschemaView RAPID software for thrombectomy trials by the interventional 
neuroradiology community. In the absence of this, a benchmark may be required 
for validating DSC-MRI post-processing tools, such as the DRO methodology 
referenced in our manuscript (Ref. [66]). In such a scenario, vendors could “test” 
their post-processing implementations against a “gold standard” to ensure that 
accurate results are obtained.  
 
To this end, we have added the following paragraph to the Summary of Updated 
Recommendations section at the end of the manuscript: 
 
“Post-processing leakage correction is beneficial, even for low FA (30°) 
acquisitions, and should be utilized in routine practice. The BSW method is an 
advisable technique for performing post-processing model-based leakage 
correction and has thus far the most computer simulation and clinical evidence to 
support its utility. In the absence of universal acceptance of a single software 
implementation for widespread use, a benchmark may be required for validating 
independent DSC-MRI post-processing tools, such as the DRO methodology 
referenced above.” 
 
There is also significant heterogeneity introduced by operator training and 
measurement techniques. Any consensus recommendations for this? Small fixed 
ROIs? Or whole lesion VOIs? Histograms? This is the other major impediment to 
generalizability of DSC MRI in trials and across sites. 
 
These are all excellent questions raised by the reviewer. For the reasons 
specified in our response to the second issue raised by Reviewer #1, we have 
focused this manuscript on consensus recommendations for the DSC-MRI 
acquisition protocol (i.e., particulars of the DSC-MRI CBV map generation 
process), including contrast agent dosing, MRI acquisition parameters, and post-
processing of the DSC-MRI signal. We have therefore purposefully avoided 
discussion of CBV analysis tools and methodologies. These are very important 
issues and would merit their own consensus recommendations. 
 
Reviewer 3  
The paper by Boxerman et al addresses a critical need for standardization of 
DSC imaging protocols for brain tumor imaging. The paper is very well written 
and provides a thorough review of the DSC literature and the challenges 
associated with DSC and multisite studies. The rationale for the 
recommendations is clearly explained and justified. I have only a few minor 
comments. 
In particular, while the authors extensively discuss the optimization of the image 
acquisition protocol, there is considerably less attention paid to the post-
processing data analysis and leakage correction. Given the importance of proper 
leakage correction, as discussed by the authors, it seems that more emphasis 
and guidance could be given for standardization of the leakage correction 
method. 
This is an excellent point raised by the reviewer. Please see our response to a 
similar query raised by Reviewer #2.  
We placed the major emphasis of this consensus protocol manuscript on the 
standardization of acquisition parameters because the DSC-MRI data can “only 
be acquired once.” Post-processing leakage correction is very important for 
obtaining accurate CBV measures, but the raw signal data can of course be 
reprocessed as algorithms evolve. In general, historical studies and the computer 
simulations cited in this manuscript have demonstrated excellent performance of 
the basic BSW technique modified for T2* correction using full-range K2 fitting. 
This would seem to be a reasonable proposal for a standardization of the 
leakage correction method. Implementations will vary, and benchmark datasets 
for ensuring the accuracy of different implementations would be helpful. 
While it is likely beyond the scope of this manuscript it might also be instructive to 
point out that the BSW method corrects only for T1 effects of extravasated 
contrast agent and not T2* effects of extravasated contrast. In some subjects the 
leakage can be so severe that T1 correction is not sufficient. Bjonerud et al tried 
to account for the T2* contribution of extravasated contrast agent by allowing the 
K2 leakage term to assume negative or positive values [1], while Mouridsen et al 
presented an abstract at the 2010 ISMRM Workshop on Improving Cancer 
Treatment with Advanced MR demonstrating a model that included T2* effects 
from extravasated contrast [2]. The K2 leakage parameter that included both T1 
and T2* leakage effects was shown to demonstrate a very similar tumor rim 
enhancement/leakage as observed in the DCE Ktrans map, while no such 
enhancement was observed in the K2 map that included only T1 correction. This 
again suggests that care must be taken for very leaky tumors where T2* effects 
from extravasated contrast agent can contribute significantly and the BSW 
correction method can fail. 
1. A Bjonerud, AG Sorensen, K. Mouridsen, KE Emblem. T1- and T2*-
dominant extravasation correction in DSC-MRI: Part I - theoretical considerations 
and implications for assessment of tumor hemodynamic properties. J Cereb 
Blood Flow Metab 2011:31;2041-2053. 
2. K Mouridsen, CT Farrar, D Jennings, K Emblem,  AG Sorensen. DSC 
Correction for Τ1 and Τ2* Relaxation Induced by Extravasated Contrast Agent. 
ISMRM Cancer Workshop 2010.  
We thank the reviewer for these insightful comments regarding the T1 and T2* 
correction in the BSW correction method. It is our understanding that most 
commercial systems that employ BSW, including the IB Neuro (Imaging 
Biometrics) implementation that was used for the in vivo comparison of the low 
FA, no preload and intermediate FA, full-dose preload schemes (Ref. [82]) do 
correct for both T1 and T2* effects by allowing K2 to either be positive or 
negative, as was done in the Bjonerud paper referenced above.   Furthermore, 
the DRO simulation studies performed by Quarles et al. (Ref. [66]) employed this 
strategy and found very high accuracy of the corrected CBV using the optimal 
acquisition parameters.  We definitely agree that care must be taken for very 
leaky tumors where T2* effects from extravasated contrast agent can contribute 
significantly, and the original unmodified BSW correction method can fail.  We 
have added reference to the Bjonerud paper on page 14 when stating that 
modifications to the original BSW method have been subsequently introduced to 
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Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI and 
evidence for its impact on the management of brain tumor patients, DSC-MRI 
methodology has not been standardized, hindering its utilization for treatment response 
assessment in multi-center trials. Recently, the DSC-MRI Standardization Subcommittee 
of the Jumpstarting Brain Tumor Drug Development Coalition used issued 
recommendations by the ASFNR as a springboard for an updated consensus DSC-MRI 
protocol compatible with BTIP, the standardized MRI brain tumor imaging protocol (BTIP) 
for high-grade gliomas that is increasingly used in the clinical setting and . BTIP is the 
default MRI protocol for the NCI’s National Clinical Trials Network and is increasingly used 
in the clinical setting. After reviewing the basis for controversy over DSC-MRI protocols, 
this manuscript provides evidence-based best practices for clinical DSC-MRI as 
determined by the Committee, including pulse sequence (gradient echo vs. spin echo), 
BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), 
and post-processing leakage correction. In summary, full-dose preload, full-dose bolus 
dosing using intermediate (60°) FA and field strength-dependent TE (40-50ms at 1.5T, 
20-35ms at 3T) provides overall best accuracy and precision for cerebral blood volume 
estimates, reiterating findings by the ASFNR. When single-dose contrast agent usage is 
desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-
dependent TE provides excellent performance, with reduced contrast agent usage and 
elimination of potential systematic errors introduced by variations in preload dose and 
incubation time and dose allocation between preload and bolus administrations. 
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In 1990, Rosen et al. demonstrated transiently decreased brain signal intensity 
after bolus administration of gadolinium-based contrast agent (GBCA).1  The signal 
intensity-time curve could be converted into a concentration-time curve, enabling voxel-
wise computation of cerebral blood volume (CBV).  This technique, now widely known as 
dynamic susceptibility contrast (DSC) MRI, uses the magnetic susceptibility properties of 
paramagnetic contrast agents (gadolinium chelates or superparamagnetic nanoparticles) 
and T2 or T2*-weighted acquisitions. DSC-MRI was used to perform the first “functional” 
MRI experiments of task-induced brain activation,2 and produce the first MRI-based CBV 
maps of gliomas.3  
Since these beginnings, studies have shown that DSC-MRI may be more useful 
than standard MRI at predicting treatment-naïve glioma grade3-8 and survival,9-13 
distinguishing post-treatment pseudoprogression and radiation necrosis from recurrent 
tumor,14-17 and predicting response to anti-angiogenic therapy.18-25  Use of DSC-MRI has 
consequently exploded over the past few decades, particularly in neuro-oncology. Geer 
et al. found that the addition of DSC-MRI increased the confidence of neuroradiologists 
and treating physicians in their assessment of tumor status in 40% and 56% of cases, 
respectively, with treatment modification in 8.5% of patients,26 highlighting the potential 
clinical impact of DSC-MRI. Despite this and other evidence for clinical impact on the 
management of brain tumor patients, technical aspects of DSC-MRI have not been 
standardized, which has hindered its widespread adoption and utilization for assessment 
of treatment response in multi-center therapeutic trials.  
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There are multiple protocol decisions for DSC-MRI that influence its practical 
implementation and the accuracy and precision of CBV measurement.27 These include 
gradient echo (GRE) versus spin echo (SE) pulse sequence; contrast agent dosing, 
including preload and bolus; image acquisition parameters, including flip angle (FA), echo 
time (TE), temporal resolution (TR) and number of baseline and post-bolus data points; 
and post-processing techniques, including GBCA leakage correction. After reviewing the 
basis for controversy over DSC-MRI protocol, this manuscript provides evidence-based 
best practices for clinical DSC-MRI, emphasizing our favored choices for these protocol 
decisions. The evidence comes from DSC-MRI theory, computer modeling and simulation 
of DSC-MRI signal acquisition and post-processing, in vivo stereotactic tissue correlation, 
and single-institution and multi-site clinical trial data. Because a primary goal for 
harmonizing DSC-MRI methodology is the facilitation of its widespread adoption and the 
collation of results from multi-site trials, for best clinical practice we emphasize CBV 
accuracy and precision in neuro-oncology applications, including treatment response 
assessment of high-grade gliomas in clinical trials of novel therapeutics. Although 
advanced DSC-MRI methods including multi-echo approaches may measure additional 
features of tumor pathophysiology (including vessel caliber, vascular permeability, tumor 
cell size and cytoarchitecture),28,29 our recommendations focus on CBV measurement 
using single TE, GRE echo planar imaging and GBCA-based DSC-MRI, which is the most 




A Brief Overview of DSC-MRI 
DSC-MRI is based upon classical indicator dilution theory used by physiologists to 
quantitate hemodynamics of whole-organ systems from known quantities of injected non-
diffusible tracers such as dyes and radiotracers, and measurement of output tracer 
concentration.31 DSC-MRI applies this methodology to the brain, using exogenous 
paramagnetic GBCA as the “tracer”. DSC-MRI is a “bolus tracking” technique that rapidly 
acquires GRE or SE echo planar images before (baseline), during (bolus), and after (tail) 
first-pass transit through the brain of GBCA that transiently alters the acquired signal 
intensity.32  Voxel-wise changes in relative contrast agent concentration are determined 
by converting the signal intensity-time curves into change in relaxation rate-time curves, 
assuming that transient signal loss is due solely to magnetic susceptibility effects resulting 
from the injected GBCA and the subsequent changes in T2* (GRE) or T2 (SE) relaxation 
rate (R2* and R2, respectively, and herein referred to collectively as R2* unless 
otherwise specified). Because R2* is assumed to be directly proportional to tissue GBCA 
concentration, with GBCA confined to the vasculature, the R2*-time curves are 
processed using tracer kinetic modeling and indicator dilution theory to estimate cerebral 
hemodynamic parameters such as CBV, cerebral blood flow (CBF), and mean transit time 
(MTT).1  Absolute CBV can theoretically be determined from the area under the R2*-
time curve normalized to the integrated arterial input function (AIF).33 Most often, to avoid 
the well-known difficulties of accurately determining the AIF, relative CBV (rCBV) is 
estimated from the area under the R2*-time curve alone giving a CBV value that has 
meaning relative to other parts of the brain. For comparison across time and patients, 
rCBV may be normalized to rCBV in normal-appearing white matter, yielding the most 
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common DSC-MRI metric for evaluating brain tumors, normalized rCBV (nRCBV).  
Alternative methods precluding the need to normalize rCBV to reference brain include 
standardization and Gaussian normalization.34,35  
Basic Contrast Mechanism for DSC-MRI 
The DSC-MRI contrast mechanism is based upon compartmentalization of 
paramagnetic GBCA that establishes magnetic susceptibility difference between the 
intra- and extra-vascular space, creating magnetic field gradients.32 Protons lose phase 
coherence as they diffuse through the transient, spatially varying gradients, yielding signal 
attenuation dependent upon physiological factors, including vessel or compartment size 
and proton diffusion rate, and experimental factors, including pulse sequence parameters 
and contrast agent concentration.36  Although this behavior can be solved analytically for 
limited regimes, this phenomenon has been most generally studied using Monte Carlo 
numerical methods that quantify the relationship between change in relaxation rate and 
the physiological and experimental parameters.36,37 These simulations yield the vessel 
size-dependence relationships for GRE (R2*) and SE (R2) change in relaxation rate, 
with R2* plateauing for large diameter vessels, and R2 peaking for capillary-sized 
vessels (e.g., Figure 1 in Ref. [36]). These relationships are qualitatively independent of 
vessel geometry.  
Gradient-echo versus Spin-echo Acquisitions 
The vessel size-dependence relationships have clinical implications. Because R2 
peaks for microvessels, SE DSC-MRI is advantageous in stroke imaging aimed at 
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identifying capillary-level perfusion deficits,38 with reduced blooming artifact in cortex 
around sulcal vessels. GRE DSC-MRI is sensitive to the larger, disorganized vessels that 
characterize high-grade gliomas,39,40 with obvious application to tumor imaging. For given 
contrast agent concentration, field strength, and imaging parameters, R2* exceeds R2 
for all vessel sizes, with larger corresponding signal loss.36 Therefore, GRE-derived CBV 
maps have higher inherent SNR and sensitivity than SE CBV maps, and can provide 
greater signal changes for equal GBCA dose, or equivalent signal changes with lower 
GBCA dose, compared to those derived with SE DSC-MRI.  
In order for DSC-MRI to accurately measure cerebral hemodynamics, there must 
be a linear relationship between change in relaxation rate and GBCA concentration. From 
basic susceptibility contrast principles, change in relaxation rate is directly proportional to 
GBCA concentration only where the R2 or R2* versus vessel size curves are 
“plateaued”.41 This plateau occurs over a much broader range of vessel sizes for GRE 
(R2*) compared to SE (R2) DSC-MRI, and so GRE CBV estimates are inherently more 
accurate than SE CBV estimates.  Similarly, the x-axis of the size-dependence curves 
actually scales as R2/D, where R is the vessel size and D is the proton diffusion rate.41 
Therefore, decreasing D (restricted diffusion) has the same effect as increasing vessel 
size (moving to the right on the change in relaxation rate versus vessel size graphs). 
While increasing vessel diameter or decreasing diffusion can result in either increased or 
decreased R2, R2* will be much less affected because of the plateau in the R2*-size 
curve. Therefore, in tumors with heterogeneous proton diffusion and abnormal vascular 
morphology, hyperintensity on CBV maps is more likely to reflect truly elevated blood 
volume for GRE acquisitions versus greater uncertainty for SE acquisitions. 
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For these reasons – sensitivity to larger, disorganized microvessels seen in higher-
grade tumors; greater signal changes for a given contrast agent dose; greater inherent 
accuracy of CBV estimates; and decreased sensitivity to changes in proton diffusion – 
GRE DSC-MRI is recommended for neuro-oncology applications. Thus, moving forward, 
we will only refer to T2* changes that occur with GRE DSC-MRI. 
Consequences of Contrast Agent Extravasation 
Another requirement for DSC-MRI to mimic tracer kinetics is that contrast agent 
must remain intravascular, which is violated for GBCAs in high-grade gliomas (HGG) with 
blood-brain barrier (BBB) disruption and avid contrast enhancement. GBCA extravasation 
results in T1 shortening, opposing the susceptibility contrast induced T2* relaxation rate 
change from intravascular GBCA that forms the basis for CBV estimation. Because GBCA 
is excluded from cells, GBCA extravasation establishes a magnetic susceptibility gradient 
not only between the intra- and extra-vascular spaces, but also between the intra- and 
extra-cellular spaces when sufficient GBCA distributes throughout the extravascular-
extracellular space, potentially exaggerating T2* changes. (As an example see Figure 5 
of Ref. [42] where in the same voxel the post-bolus signal can overshoot or undershoot 
baseline depending upon the accumulated dose of GBCA.) DSC-MRI signal is thereby 
affected not only by vascular volume fraction and vessel size, but also by the rate of 
GBCA extravasation (vascular permeability) and the cell volume fraction, cell size and 
cell distribution.28  Signal-time (and R2*-time) curves no longer return to baseline as they 
do for ideal tracer kinetics, but extend below or above baseline depending on whether T1 
or T2* effects dominate, thereby affecting the accuracy of CBV estimates determined from 
 N-O-D-20-00183R1 
 13 
the area under the R2*-time curve.43 The magnitude of this effect depends upon a 
combination of both DSC-MRI acquisition parameters and contrast agent dosing.42   
Methods for minimizing DSC-MRI signal contamination from GBCA extravasation 
include low FA pulse sequences that reduce T1 sensitivity;44 loading doses or “preload” 
contrast administration;5,8,45 and post-processing techniques including model-based 
leakage correction that can rectify both T1 and T2* leakage effects.5,8,45-47  Dual-echo 
DSC-MRI utilizes two GRE acquisitions with different TEs to estimate change in relaxation 
rate directly, thereby eliminating T1 contamination effects entirely, but still requires 
correction for T2* leakage effects48 and special pulse sequences that are less widely 
available.38,49 No technique has been universally accepted, and much of the debate about 
best DSC-MRI methodology centers on issues related to minimizing contamination of the 
DSC-MRI signal due to GBCA extravasation and maximizing CBV accuracy.  
Intravascular contrast agents like ferumoxytol eliminate contrast agent leakage 
effects entirely, and there is compelling evidence that ferumoxytol-based CBV 
measurements are inherently more accurate and precise than gadolinium-based CBV 
measurements because complications related to GBCA extravasation are minimized.50  
However, clinical application of ferumoxytol-based DSC-MRI may be limited. FDA-
approved as a therapeutic iron supplement, ferumoxytol is less commonly available than 
GBCA for MRI. GBCAs are widely accepted by radiologists for conventional post-contrast 
imaging and adding a second contrast agent for DSC-MRI would be logistically 
challenging. Although conventional contrast-enhanced imaging is feasible with 
ferumoxytol, it is practically performed 24 hours after agent administration.51  
Furthermore, the standardized BTIP requires post-contrast imaging after one total dose 
 N-O-D-20-00183R1 
 14 
of GBCA.30 Finally, gadolinium-based DSC-MRI permits measurement of additional 
physiological parameters related to GBCA extravasation, such as PSR (percent signal 
recovery of the signal-time curve compared to baseline), as well as Ktrans (volume transfer 
coefficient of gadolinium from the intravascular to the extravascular, extracellular space). 
Therefore, we focus on single-GRE GBCA-based DSC-MRI and the selection of four 
fundamental protocol choices: preload and bolus contrast agent dose, FA, TE, and post-
processing leakage correction.  
Preload Contrast Agent Dosing 
A “preload” dose of GBCA administered prior to the bolus dose of GBCA given 
during dynamic imaging can help mitigate T1 contamination. The preload dose partially 
saturates baseline T1-weighted signal contribution,5,8,45 thereby diminishing T1-induced 
increased signal during bolus passage. Evidence supporting preload administration 
includes data in a C6 rat glioma model, where (at least for high-FA acquisitions) there is 
no discernable DSC-MRI signal after the first (no preload) injection, and a “usable” DSC-
MRI signal for computing CBV with the second injection.46 A study comparing several 
different approaches for acquiring and computing rCBV maps in patients demonstrated 
that without preload, high-grade tumor may mistakenly show no rCBV elevation compared 
to normal brain, but expected rCBV elevation is found when a preload was used.42 
Preload dosing has varied in the literature, ranging from fractional doses up to a full 
equivalent dose. In a study using a 60° FA and post-processing leakage correction, Hu et 
al. found that a full-dose preload of 0.1 mmol/kg and an incubation time of 6 minutes 
between preload administration and bolus injection optimized the separation of CBVs for 
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tumor and treatment effect in HGGs with recurrent enhancement after standard 
chemoradiation.52  
Post-Processing Leakage Correction 
In practice, DSC-MRI acquisition cannot be decoupled from post-processing, and 
there is ample evidence that post-processing leakage-correction of DSC-MRI data is 
necessary for accurate rCBV measurement when the BBB is disrupted.5,8,45  A 
pharmacokinetic model-based approach described by Weisskoff et al.53 was the first 
published method for correcting T1-based GBCA leakage effects using a linear least-
squares fit of the R2*-time curves within the tumor and a reference region in non-
enhancing brain to correct the entire R2*-time curve, including first pass.5,8,45,46  The 
method was subsequently modified to correct T2* leakage effects as well,45,54 and it was 
empirically determined that the algorithm performed best with the collection of 120 time 
points, a finding consistent with the assumption of no contrast agent backflux. This 
leakage correction method is now sometimes referred to as the BSW method (after the 
authors of the subsequent paper that focused exclusively on the leakage correction 
algorithm8).   
Modifications to the BSW approach have since been published, including 
calculation of the tissue residue function allowing for a voxel-wise correction of the raw 
DSC-MRI signal that is insensitive to variations in MTT.46 The ability to determine 
additional perfusion parameters directly from the residue function has also been 
demonstrated.54 Most recently, a “bidirectional” version of the BSW method was 
developed that accounts for backflux of contrast agent,47,55 which becomes important with 
 N-O-D-20-00183R1 
 16 
the collection of >120 time points.  While other leakage correction methods like gamma-
variate fitting and post-bolus baseline correction have been used, studies suggest that 
these do not perform as well because they do not correct for leakage effects occurring 
throughout the DSC bolus.42,46  
Preload and model-based post-processing leakage correction are synergistic in 
their improvement of rCBV accuracy,42 and consensus recommendations for leakage-
corrected, single-echo DSC-MRI have been directed towards a technique combining the 
two methods.56  For high FA, rCBV using preload plus leakage correction strongly 
correlates with tumor grade, whereas uncorrected rCBV does not,8 and in a rat 
gliosarcoma model, combined preload and post-processing leakage correction yield CBV 
estimates that converge to gold standard values obtained using MION, an intravascular 
contrast agent.57  RCBV measurements using preload and the BSW method agree well 
with histology in spatially correlated tissue biopsies,58,59 and the BSW method has been 
applied in single-institution studies and multi-site clinical trials demonstrating, among 
other benefits, the utility of rCBV for predicting or detecting early responses to 
therapy.20,23,60,61  Nonetheless, there are potentially important improvements to be gained 
using modified BSW approaches that have yet to be thoroughly evaluated.   
Although the BSW method has been implemented by several commercial software 
vendors, discrepancies in computed rCBV arise in head-to-head comparisons,62 and 
caution is recommended for cross-platform comparisons. For instance, significantly 
different performance was observed when identical DSC-MRI data were processed with 
two software packages using different implementations of post-processing leakage 
correction.62 The best correlation of CBV with histology required preload plus post-
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processing leakage correction, providing evidence that leakage correction is important 
but that technique and implementation matter.  Marked inter-site disagreement has also 
been observed when site-specific software was applied to DSC-MRI data generated by a 
digital reference object (DRO) using a standardized imaging protocol.63 Nonetheless, it 
has been shown that when a single data set is carefully pre-processed eliminating 
differences in intermediate analysis steps (such as ROI selection and registration), then 
rCBV values computed by multiple sites using different platforms begin to converge,64 
and a “consensus” threshold is reached for distinguishing low-grade from high-grade 
gliomas. Therefore, implementation matters, motivating efforts to build consensus 
regarding post-processing and to establish a benchmark for validating DSC-MRI analysis 
tools, such as the DRO described below.65,66 
Impact of Flip Angle and TE 
For single-echo DSC-MRI, low to intermediate FA (i.e. 35°–60°) with longer TR 
(i.e. 1.2–1.7s) and TE (i.e. >20ms) can reduce T1 contamination due to GBCA 
extravasation.44 However, some parameter combinations may also reduce the SNR of 
the computed rCBV maps,67 and the goal is to minimize leakage effects while maintaining 
SNR.  Accordingly, there are high- and low-FA DSC-MRI strategies with tradeoffs, as 
summarized in Table 1. Acquisitions using low FA,44 long TE,68 and long TR69 have 
decreased T1 sensitivity, and less need for preload, but poorer CBV SNR. Higher FA,8 
shorter TE,70 and shorter TR67 may require preload to decrease T1 sensitivity, but have 
higher CBV SNR. 
We have direct validation of CBV accuracy using two different acquisition 
strategies. Stereotactic biopsies co-registered to leakage-corrected CBV maps made with 
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preload, 60° FA, and post-processing leakage correction have shown excellent 
correlation of CBV with histologic vascular area and density.58 Similarly, stereotactic 
biopsies co-registered to CBV maps made using no preload, a low FA (35°), and no 
model-based leakage correction also had good correlation of CBV with microvascular 
expression.71 The literature is replete with conflicting acquisition strategies such as these. 
Motivation for Standardization of DSC-MRI Methodology 
The application of DSC-MRI to treatment response assessment of HGGs 
illustrates the importance of harmonization of DSC-MRI methodology. There has been 
much investigation of the use of CBV for differentiating true tumor from treatment effects. 
Relative CBV has putative value for differentiating progressive disease (PD) 
characterized by enlarged microvessels with high vascular density from treatment effects 
characterized by inflammatory or steroid-like behavior as in pseudoprogression (PsP) or 
pseudoresponse, respectively.72-74  
CBV has been used to distinguish PsP and PD at initial progressive contrast 
enhancement after chemoradiation but the literature is somewhat conflicting. For 
instance, Prager et al. studied 68 HGGs at progressive enhancement and found 
significant difference in median rCBV between PsP and PD, with an optimal threshold of 
1.3.75 Other studies also found mean or median CBV to be predictive, with varying 
thresholds,19,76 but others have found mean CBV to be non-predictive or only predictive 
with qualification. Although Kong et al. found overall significant difference in mean rCBV 
between PsP and PD, this difference applied to GBMs with unmethylated but not with 
methylated MGMT.77  However, a study of HGGs treated with PPX, a powerful radiation 
sensitizer with a high incidence of PsP often coincident with PD, found no significant 
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difference in mean rCBV between PsP and PD at initial progressive enhancement.78 
These are just a few examples of varied results in the literature. 
Variability of DSC-MRI Methodology in the Literature 
Literature results may conflict at least in part because DSC-MRI methodology 
varies greatly. Patel et al. published a meta-analysis of 17 studies where DSC-MRI was 
used to differentiate recurrent HGG from treatment-related enhancement.79  For the 
subgroup of studies using mean lesion rCBV, they found “relatively good accuracy in 
individual studies” with high pooled sensitivity (88% [0.81-0.94]) and specificity (88% 
[0.78-0.95]) for recurrent tumor, but there was a wide range of optimal mean CBV 
thresholds (0.9–2.15). This variation has been attributed to the wide range of TR, TE, FA, 
preload dose and post-processing leakage correction used by these studies, as 
summarized in Figure 1. Variable parameters are also found in subsequent literature.  For 
instance, using spatially correlated histologic tissue samples, TR = 1100-1250ms, 
TE = 30ms, FA = 70-80°, ½-1 dose preload with full-dose bolus, and post-processing 
leakage correction (IB Neuro), Prah et al. found a nRCBV cutoff of 1.13 with 82% 
sensitivity and 90% specificity.59 Patel et al. concluded that “because of significant 
variability in optimal reported thresholds…further investigation and standardization is 
needed before implementing any particular quantitative PWI strategy across institutions.” 
On a similar note, Quarles et al. organized a Quantitative Imaging Network (QIN) 
DSC-MRI challenge with 12 NCI-QIN centers to explore factors related to CBV 
consistency.63 They simulated a 10,000-voxel population-based DRO for each site’s 
DSC-MRI protocol (19 total protocols),65 and used corresponding DSC-MRI signal curves 
 N-O-D-20-00183R1 
 20 
for three evaluations of inter-site CBV consistency: central processing of CBV for site-
specific DROs (isolated impact of acquisition protocol); site-specific processing of CBV 
for standard DRO (isolated impact of post-processing methodology); and site-specific 
processing of CBV for site-specific DROs (combined impact of acquisition and post-
processing). The 3T DSC-MRI acquisition protocol varied considerably for the 12 sites 
(15 paradigms). Though TR and TE were relatively consistent (possibly reflecting 
adoption of previously published protocol recommendations56), FA and preload dosing 
varied considerably, with a wide gamut of post-processing methodology, including 
software, integration limits, and normalization to white matter. When local sites chose 
both acquisition and post-processing, there was very poor cross-site intra-class 
correlation for CBV, particularly for simulated blood-brain barrier disruption typical for 
GBMs, and with large limits of agreement on Bland-Altman analysis. There was better 
correlation when acquisition or post-processing was standardized, especially post-
processing. Overall, this study demonstrates that CBV variability can arise from 
differences in post-processing as well as image acquisition. This has profound 
implications for comparing literature CBV values from sites using dissimilar acquisition 
and post-processing schemes. For clinical trials, although acquisition and post-
processing methods are typically standardized, the most accurate and proven 
approaches should be used for determining the therapeutic effectiveness of a drug, or 
establishing thresholds for categorical response (e.g., predetermined changes in CBV 
used to refine RANO criteria). 
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Previous Efforts at Standardization: ASFNR White Paper (2015) 
Efforts at standardization have been made by several organizations including the 
ASFNR, which published a white paper with the following recommendations: single-echo, 
GRE pulse sequence; TR = 1.0-1.5s; TE = 40-45ms at 1.5T, 25-35ms at 3T; FA = 60-70°; 
acquisition duration of at least 120 total time points, including at least 30-50 baseline 
acquisitions; and ¼-1 dose preload with full-dose bolus.56  These recommendations were 
made prior to the publication of the standardized BTIP,30 which is gaining clinical 
acceptance. 
BTIP Compliance and Implication for Allowable Dosing Schemes 
It is sensible that a standardized DSC-MRI protocol be compatible with BTIP. BTIP 
mandates that conventional post-contrast T1-weighted imaging be performed after one 
full dose of GBCA, either split between preload and DSC-MRI bolus before post-contrast 
imaging, or fully given as preload with variable bolus dose DSC-MRI after post-contrast 
imaging. This sets constraints on the range of preload and bolus doses that should be 
considered for inclusion in a universal DSC-MRI protocol. Possible BTIP-compliant DSC-
MRI preload and bolus paradigms are illustrated in Figure 2. 
Selection of Optimal DSC-MRI Parameters: Computational Approach 
Because it is impractical to compare all possible acquisition schemes in vivo, 




Using a multi-compartment model-based simulation of DSC-MRI signal derived 
from convolution theory,80 the theoretical framework developed by Quarles et al.,43 and 
characteristics from 250 randomly chosen tumors, Leu et al. systematically evaluated the 
effects of various acquisition and post-processing leakage correction strategies, including 
a range of FA, TE, and TR with BTIP-compliant contrast agent dosing schemes, on the 
fidelity of CBV estimation in the presence of Gaussian noise.81 Results of this 
comprehensive study are summarized in Figure 3. Although no single acquisition scheme 
was absolutely optimal, several parameter combinations yielded the lowest error in CBV 
estimation. The best performing acquisition schemes included 60° FA with full-dose 
preload and full-dose bolus (“1+1” double-dose GBCA), as well as 35° FA without preload. 
Importantly, high-FA acquisitions with no or fractional preload dosing performed relatively 
poorly.  
Similarly, Semmineh et al. used a validated population-based DRO, derived from 
3D tumor tissue microstructures and trained on 23 DSC-MRI glioblastoma datasets 
including more than 40,000 voxels.65 They simulated tumor CBV acquired with BTIP-
compliant dosing schemes, and a similar range of FA, TE, and TR. Simulated CBV without 
leakage was the reference standard, and they evaluated concordance correlation 
coefficient and coefficient of variation as measures of accuracy and precision, 
respectively. They produced heat maps with similar findings as Leu et al. The best 
performing schemes used full-dose preload and full-dose bolus at low to intermediate FA, 
with poor performance for intermediate-high FAs using no or fractional preload, 
particularly at 1.5 T.66 Confluent regions of high performance are desirable because these 
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schemes would presumably be less sensitive to minor parameter variations or to 
underlying model assumptions or tumor physiology. 
Figure 4 summarizes performance of the intermediate 60° FA scheme from the 
ASFNR white paper versus a high-performing, low FA scheme for TR=1.5s.  Full-dose 
preload with full-dose bolus (“1+1” double-dose GBCA) provides the highest accuracy 
and precision for both schemes with similar performance at 1.5 and 3T.  With intermediate 
FA, single total dose schemes have poorer performance, especially at 1.5T, with 
moderate performance for split dose at 3T. Low FA acquisitions give much better 
performance for single total dose. For single-dose contrast without preload, the ASFNR 
parameters (i.e., intermediate FA) perform poorly, but low FA maintains excellent 
performance, even at 1.5T. Non-BTIP compliant preload dosing (e.g., ½ or ¼ dose) with 
full-dose bolus can give excellent results with low FA and intermediate FA at 3T, and very 
good results at 1.5T. 
Convergence of results from these simulations suggest that even without preload 
(i.e., “0+1” dosing), a low FA scheme gives very accurate CBV with much less bias 
compared to intermediate FA, even at 1.5T, and could be an attractive approach requiring 
less contrast agent (Figure 5A). 
With the application of simultaneous multi-slice or multi-band techniques, it is 
possible to shorten the temporal resolution to sub-second TRs, while maintaining 
sufficient spatial coverage. DRO-based recommendations for TR, TE, and FA seek the 
optimal T1 and T2* sensitivity, and sub-second TRs will increase sensitivity to T1 leakage 
effects and reduce rCBV fidelity. For example, the DRO analysis for “0+1” dosing and the 
optimal low FA approach described above (30° FA, 30ms TE) predicts that the 
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concordance correlation coefficient (CCC), a measure of CBV accuracy, drops to 0.76 
and 0.62 for TR=750ms and 500ms, respectively. Even if TE is increased to 50ms, CBV 
accuracy is lower (CCC<0.9) than that achieved using more conventional TRs (1–1.5s). 
However, for “1+1” dosing and the optimal low FA scheme, the CCC exceeds 0.95, even 
for TRs as low as 500ms. These results highlight the importance of parameter 
consistency and encourage caution when applying acceleration techniques. 
In vivo Assessment of Low FA, No Preload DSC-MRI 
A recent study was performed to validate in vivo the simulations predicting that 
single-dose, low-FA DSC-MRI acquisitions without preload (“0+1” dosing) give rCBV 
estimates practically equivalent to the double-dose, intermediate-FA reference standard 
using full-dose preload (“1+1” dosing).82  84 patients with a contrast-enhancing brain 
lesion were included in this four-institution study.  As shown in Figure 5B, the study 
demonstrated practical equivalence between the two methods, supporting the idea that 
this low-dose approach should be considered for consensus protocol recommendation, 
at least at 3T.  The agreement between the two methods was poor if post-processing 
leakage correction (BSW method) was not also applied. Confirmation of equivalence at 
1.5T requires a similar study. 
Conclusions from Computational Parameter Analyses and In Vivo 
Comparison Study 
Based on the recent literature, the following conclusions can be drawn regarding 
DSC-MRI acquisition methodology: 
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1) Of the BTIP-compliant dosing schemes investigated, full-dose preload with full-dose 
bolus (“1+1” dosing) has superior performance, with the least sensitivity to minor pulse 
sequence parameter fluctuations and the best combination of accuracy and precision, 
which is important for clinical trials that aim to minimize sample size. Although both low 
FA (30°) and intermediate FA (60°) sequences provide a high degree of accuracy in 
simulations testing the “1+1” dosing scheme, we continue to consider intermediate FA 
(60°) to be the gold standard for “1+1” dosing, particularly at 3T field strength, given the 
benefits of higher CNR and lower sensitivity to parameter variations (e.g., TE, TR) 
compared to low FA (30°) acquisitions. 
2) When the “1+1” dosing scheme is not desirable (e.g., when prioritizing low GBCA 
dosage), the no-preload paradigm (“0+1” dosing) with low FA (30°) and an optimally 
selected and field-strength dependent TE provides an excellent practical alternative to 
the gold standard and is the recommended alternative method, particularly at 3T for which 
in vivo validation has been performed.  Based on simulation testing of the “0+1” dosing 
scheme, low FA (30°) acquisitions provide superior accuracy and precision compared to 
the intermediate FA (60°).  This appears to hold true at both 1.5T and 3T field strengths 
(though has not yet been validated in vivo at 1.5T).  
3) For both the “1+1” dosing at intermediate FA (60°) and “0+1” dosing at low FA (30°), 
there is a modest theoretical performance advantage at 3T versus 1.5T. 
4) For BTIP-compliant fractional dosing (e.g., “½+½”and “¼+¾” dosing schemes), a low 
FA (30°) acquisition should be used at all field strengths, given the superior accuracy and 
precision compared to intermediate FA (60°) acquisitions, with TE = 30-50ms having 
theoretical advantages, especially at 1.5T.  However, these fractional dosing schemes 
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likely have poorer performance than the “0+1” dosing scheme and the gold-standard 
“1+1” dosing scheme, due to the theoretical costs of poor CNR for fractional bolus dosing, 
particularly for perfusion metrics such as cerebral blood flow CBF and MTT.    
5) Post-processing leakage correction is always beneficial, even for low FA (30°) 
acquisitions, and should be utilized in routine practice.  
Time-point specifications 
Number of baseline time points 
Because the number of baseline acquisitions impacts CBV map SNR, image 
acquisition should begin at least 30–50 time points before contrast injection via a power 
injector.67 
Number of post-bolus time points 
Post-processing leakage-correction algorithms and PSR analysis utilize post-bolus 
“tail” signal intensities, necessitating acquisition of sufficient post-bolus time points. 120 
total time points (for a typical TR of 1.0–1.5s) have been shown by simulation to yield 
optimal results using the BSW post-processing leakage correction methodology and a 
30-50 time point baseline.66  For longer total acquisitions (e.g., 180 time points), reflux of 
contrast agent back into blood vessels is more likely to occur, violating assumptions of 
unidirectional contrast agent efflux.8  In such cases, bidirectional contrast agent leakage 
correction schemes are more accurate,47 with similar accuracy for unidirectional and 
bidirectional leakage correction when 120 total time points are acquired.66 
 N-O-D-20-00183R1 
 27 
Compatibility with DCE-MRI 
When acquisition of both DCE- and DSC-MRI is desired for a single exam, DCE-
MRI is typically performed using the preload dose for DSC-MRI. Preload-based, BTIP-
compliant dosing strategies that have been previously evaluated include the “1+1” and 
“½+½” protocols.  Due to the higher CNR of full-dose acquisitions, the “1+1” dosing 
scheme provides superior DCE- and DSC-parameter accuracy and precision. However, 
as highlighted in Figure 4, the “½+½” protocol with low FA (30°) provides a reasonable 
alternative with a modest reduction in accuracy and precision. It is important to note that 
although the DSC-MRI preload could be used for DCE-MRI, dosage needs to be guided 
by both DCE-MRI requirements and BTIP compliance, and further investigation is 
required for determining the fidelity and clinical utility for candidate dosing strategies.  
Summary of Updated Recommendations for DSC-MRI Parameters 
In light of the emergence of the BTIP standards,30 recent computer simulation 
results,66,81 and multi-site in vivo validation,82 our committee is proposing several 
modifications to the previously published ASFNR recommendations. Because adoption 
of DSC-MRI is anticipated for multi-site trials, our modified DSC-MRI protocol is BTIP-
compliant, imposing constraints on contrast agent preload and bolus selection. 
From a theoretical perspective, a full-dose preload, full-dose bolus dosing scheme 
(“1+1”), using low (30°) or intermediate (60°) FA and field strength-dependent TE (40-
50ms at 1.5T, 25-35ms at 3T) provides overall best performance based upon accuracy 
and precision estimates. In clinical trials or at independent clinical sites where double 
contrast agent dose is acceptable and highest performance is desired, the double-dose 
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(“1+1”) approach can be used. However, when single-dose GBCA usage is desired or 
required, we recommend a no-preload, full-dose bolus dosing scheme (“0+1”) using low 
FA (30°) and field strength-dependent TE (40-50ms at 1.5T, 25-35ms at 3T). For most 
typical applications and with excellent performance preservation, the “0+1” approach has 
advantages, including reduced GBCA usage, as well as elimination of potential 
systematic error introduced by variation in incubation time between preload and bolus 
administrations. Although the no-preload, low-FA scheme has slightly poorer accuracy 
and precision than the full-dose preload, full-dose bolus scheme, the “1+1” scheme uses 
more GBCA, and that downside may more than outweigh the slight gain in performance. 
Even the fractional dosing schemes (“¼+¾” and “½+½”), with near equivalent 
performance using low FA, still have the disadvantage of requiring preload, and potential 
variation in incubation times can lead to systematic errors. Therefore, the no-preload 
“0+1” protocol may be most appropriate for routine clinical use.   
Post-processing leakage correction is beneficial, even for low FA (30°) 
acquisitions, and should be utilized in routine practice. The BSW method is an advisable 
technique for performing post-processing model-based leakage correction and has thus 
far the most computer simulation and clinical evidence to support its utility. In the absence 
of universal acceptance of a single software implementation for widespread use, a 
benchmark may be required for validating independent DSC-MRI post-processing tools, 
such as the DRO methodology referenced above. 
The updated DSC-MRI protocol recommendations are summarized in Table 2.  
Integrated BTIP and DSC-MRI protocols for the “0+1” and “1+1” dosing schemes are 
summarized in Supplemental Table 1 and Table 2, respectively.  
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As a final thought, it is worth noting that although the updated DSC-MRI protocol 
is motivated by theory, computer simulations, in vivo studies, and clinical trial data related 
to high-grade gliomas, the principles apply to any contrast-enhancing brain lesion, 
including metastases and active inflammation or infection. Therefore, we believe that the 
protocol recommendations herein are generally applicable to routine clinical practice. 
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Figure 1.  
DSC-MRI methodology in the literature varies greatly, as seen in the subgroup meta-
analysis by Patel et al. of studies using mean lesion rCBV for recurrent high-grade tumor 
vs. treatment effect. These studies used a wide range of DSC-MRI parameters including 
TE, FA, preload dose and post-processing leakage correction (PPLC). (Adapted from Ref. 
[79].)  
Figure 2.  
Possible BTIP-compliant DSC-MRI preload + bolus dose paradigms. Either a single total 
dose must be split between preload and DSC-MRI before post-GBCA imaging, or a full 
dose preload must be given with DSC-MRI after post-contrast imaging. 
Figure 3.  
Computational approach for determining optimal BTIP-compliant DSC-MRI parameters 
using simulated DSC-MRI signal with GBCA leakage: heat maps of CBV error versus 
theoretical CBV without leakage for different combinations of acquisition parameters. 
Schemes with particularly high fidelity at 3T include 60° FA with full-dose preload and 
bolus (asterisk with dashed box) and low FA without preload (asterisk with solid box). 
(Adapted from Ref. [81].) 
Figure 4.  
Computational approach for determining optimal BTIP-compliant DSC-MRI parameters 
using a digital reference object matched to glioblastoma training data: performance 
comparison for intermediate and low flip angle schemes. For double-dose contrast with 
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full-dose preload, both schemes have excellent accuracy and precision at 1.5T and 3T. 
For single-dose contrast without preload, intermediate FA performs poorly but low FA 
maintains excellent performance, even at 1.5T. For each dosing scheme, low FA had 
equal or better performance than intermediate FA. CCC = Concordance correlation 
coefficient (accuracy); CV = coefficient of variation (precision). (Adapted from Ref. [66].) 
Figure 5.  
A) DRO-based simulations demonstrate that even without preload, low FA (30°) 
acquisitions give very accurate CBV (along the line of unity) with much less bias 
compared to intermediate FA (60°) acquisitions, even at 1.5T. (Adapted from Ref. [66].) 
B) Excellent CBV agreement has been observed in vivo at 3T for “0+1” and “1+1” dosing 
schemes, according to Lin’s concordance correlation (CCC). 
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Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-
MRI methodology has not been standardized, hindering its utilization for response 
assessment in multi-center trials. Recently, the DSC-MRI Standardization Subcommittee 
of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated 
consensus DSC-MRI protocol compatible with BTIP, the standardized brain tumor 
imaging protocol for high-grade gliomas that is increasingly used in the clinical setting 
and is the default MRI protocol for the National Clinical Trials Network. After reviewing 
the basis for controversy over DSC-MRI protocols, this manuscript provides evidence-
based best practices for clinical DSC-MRI as determined by the Committee, including 
pulse sequence (gradient echo vs. spin echo), BTIP-compliant contrast agent dosing 
(preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage 
correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) 
FA and field strength-dependent TE (40-50ms at 1.5T, 20-35ms at 3T) provides overall 
best accuracy and precision for cerebral blood volume estimates. When single-dose 
contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) 
and field strength-dependent TE provides excellent performance, with reduced contrast 
agent usage and elimination of potential systematic errors introduced by variations in 
preload dose and incubation time. 





In 1990, Rosen et al. demonstrated transiently decreased brain signal intensity 
after bolus administration of gadolinium-based contrast agent (GBCA).1  The signal 
intensity-time curve could be converted into a concentration-time curve, enabling voxel-
wise computation of cerebral blood volume (CBV).  This technique, now widely known as 
dynamic susceptibility contrast (DSC) MRI, uses the magnetic susceptibility properties of 
paramagnetic contrast agents (gadolinium chelates or superparamagnetic nanoparticles) 
and T2 or T2*-weighted acquisitions. DSC-MRI was used to perform the first “functional” 
MRI experiments of task-induced brain activation,2 and produce the first MRI-based CBV 
maps of gliomas.3  
Since these beginnings, studies have shown that DSC-MRI may be more useful 
than standard MRI at predicting treatment-naïve glioma grade3-8 and survival,9-13 
distinguishing post-treatment pseudoprogression and radiation necrosis from recurrent 
tumor,14-17 and predicting response to anti-angiogenic therapy.18-25  Use of DSC-MRI has 
consequently exploded over the past few decades, particularly in neuro-oncology. Geer 
et al. found that the addition of DSC-MRI increased the confidence of neuroradiologists 
and treating physicians in their assessment of tumor status in 40% and 56% of cases, 
respectively, with treatment modification in 8.5% of patients,26 highlighting the potential 
clinical impact of DSC-MRI. Despite this and other evidence for clinical impact on the 
management of brain tumor patients, technical aspects of DSC-MRI have not been 
standardized, which has hindered its widespread adoption and utilization for assessment 
of treatment response in multi-center therapeutic trials.  
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There are multiple protocol decisions for DSC-MRI that influence its practical 
implementation and the accuracy and precision of CBV measurement.27 These include 
gradient echo (GRE) versus spin echo (SE) pulse sequence; contrast agent dosing, 
including preload and bolus; image acquisition parameters, including flip angle (FA), echo 
time (TE), temporal resolution (TR) and number of baseline and post-bolus data points; 
and post-processing techniques, including GBCA leakage correction. After reviewing the 
basis for controversy over DSC-MRI protocol, this manuscript provides evidence-based 
best practices for clinical DSC-MRI, emphasizing our favored choices for these protocol 
decisions. The evidence comes from DSC-MRI theory, computer modeling and simulation 
of DSC-MRI signal acquisition and post-processing, in vivo stereotactic tissue correlation, 
and single-institution and multi-site clinical trial data. Because a primary goal for 
harmonizing DSC-MRI methodology is the facilitation of its widespread adoption and the 
collation of results from multi-site trials, for best clinical practice we emphasize CBV 
accuracy and precision in neuro-oncology applications, including treatment response 
assessment of high-grade gliomas in clinical trials of novel therapeutics. Although 
advanced DSC-MRI methods including multi-echo approaches may measure additional 
features of tumor pathophysiology (including vessel caliber, vascular permeability, tumor 
cell size and cytoarchitecture),28,29 our recommendations focus on CBV measurement 
using single TE, GRE echo planar imaging and GBCA-based DSC-MRI, which is the most 




A Brief Overview of DSC-MRI 
DSC-MRI is based upon classical indicator dilution theory used by physiologists to 
quantitate hemodynamics of whole-organ systems from known quantities of injected non-
diffusible tracers such as dyes and radiotracers, and measurement of output tracer 
concentration.31 DSC-MRI applies this methodology to the brain, using exogenous 
paramagnetic GBCA as the “tracer”. DSC-MRI is a “bolus tracking” technique that rapidly 
acquires GRE or SE echo planar images before (baseline), during (bolus), and after (tail) 
first-pass transit through the brain of GBCA that transiently alters the acquired signal 
intensity.32  Voxel-wise changes in relative contrast agent concentration are determined 
by converting the signal intensity-time curves into change in relaxation rate-time curves, 
assuming that transient signal loss is due solely to magnetic susceptibility effects resulting 
from the injected GBCA and the subsequent changes in T2* (GRE) or T2 (SE) relaxation 
rate (R2* and R2, respectively, and herein referred to collectively as R2* unless 
otherwise specified). Because R2* is assumed to be directly proportional to tissue GBCA 
concentration, with GBCA confined to the vasculature, the R2*-time curves are 
processed using tracer kinetic modeling and indicator dilution theory to estimate cerebral 
hemodynamic parameters such as CBV, cerebral blood flow (CBF), and mean transit time 
(MTT).1  Absolute CBV can theoretically be determined from the area under the R2*-
time curve normalized to the integrated arterial input function (AIF).33 Most often, to avoid 
the well-known difficulties of accurately determining the AIF, relative CBV (rCBV) is 
estimated from the area under the R2*-time curve alone giving a CBV value that has 
meaning relative to other parts of the brain. For comparison across time and patients, 
rCBV may be normalized to rCBV in normal-appearing white matter, yielding the most 
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common DSC-MRI metric for evaluating brain tumors, normalized rCBV (nRCBV).  
Alternative methods precluding the need to normalize rCBV to reference brain include 
standardization and Gaussian normalization.34,35  
Basic Contrast Mechanism for DSC-MRI 
The DSC-MRI contrast mechanism is based upon compartmentalization of 
paramagnetic GBCA that establishes magnetic susceptibility difference between the 
intra- and extra-vascular space, creating magnetic field gradients.32 Protons lose phase 
coherence as they diffuse through the transient, spatially varying gradients, yielding signal 
attenuation dependent upon physiological factors, including vessel or compartment size 
and proton diffusion rate, and experimental factors, including pulse sequence parameters 
and contrast agent concentration.36  Although this behavior can be solved analytically for 
limited regimes, this phenomenon has been most generally studied using Monte Carlo 
numerical methods that quantify the relationship between change in relaxation rate and 
the physiological and experimental parameters.36,37 These simulations yield the vessel 
size-dependence relationships for GRE (R2*) and SE (R2) change in relaxation rate, 
with R2* plateauing for large diameter vessels, and R2 peaking for capillary-sized 
vessels (e.g., Figure 1 in Ref. [36]). These relationships are qualitatively independent of 
vessel geometry.  
Gradient-echo versus Spin-echo Acquisitions 
The vessel size-dependence relationships have clinical implications. Because R2 
peaks for microvessels, SE DSC-MRI is advantageous in stroke imaging aimed at 
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identifying capillary-level perfusion deficits,38 with reduced blooming artifact in cortex 
around sulcal vessels. GRE DSC-MRI is sensitive to the larger, disorganized vessels that 
characterize high-grade gliomas,39,40 with obvious application to tumor imaging. For given 
contrast agent concentration, field strength, and imaging parameters, R2* exceeds R2 
for all vessel sizes, with larger corresponding signal loss.36 Therefore, GRE-derived CBV 
maps have higher inherent SNR and sensitivity than SE CBV maps, and can provide 
greater signal changes for equal GBCA dose, or equivalent signal changes with lower 
GBCA dose, compared to those derived with SE DSC-MRI.  
In order for DSC-MRI to accurately measure cerebral hemodynamics, there must 
be a linear relationship between change in relaxation rate and GBCA concentration. From 
basic susceptibility contrast principles, change in relaxation rate is directly proportional to 
GBCA concentration only where the R2 or R2* versus vessel size curves are 
“plateaued”.41 This plateau occurs over a much broader range of vessel sizes for GRE 
(R2*) compared to SE (R2) DSC-MRI, and so GRE CBV estimates are inherently more 
accurate than SE CBV estimates.  Similarly, the x-axis of the size-dependence curves 
actually scales as R2/D, where R is the vessel size and D is the proton diffusion rate.41 
Therefore, decreasing D (restricted diffusion) has the same effect as increasing vessel 
size (moving to the right on the change in relaxation rate versus vessel size graphs). 
While increasing vessel diameter or decreasing diffusion can result in either increased or 
decreased R2, R2* will be much less affected because of the plateau in the R2*-size 
curve. Therefore, in tumors with heterogeneous proton diffusion and abnormal vascular 
morphology, hyperintensity on CBV maps is more likely to reflect truly elevated blood 
volume for GRE acquisitions versus greater uncertainty for SE acquisitions. 
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For these reasons – sensitivity to larger, disorganized microvessels seen in higher-
grade tumors; greater signal changes for a given contrast agent dose; greater inherent 
accuracy of CBV estimates; and decreased sensitivity to changes in proton diffusion – 
GRE DSC-MRI is recommended for neuro-oncology applications. Thus, moving forward, 
we will only refer to T2* changes that occur with GRE DSC-MRI. 
Consequences of Contrast Agent Extravasation 
Another requirement for DSC-MRI to mimic tracer kinetics is that contrast agent 
must remain intravascular, which is violated for GBCAs in high-grade gliomas (HGG) with 
blood-brain barrier (BBB) disruption and avid contrast enhancement. GBCA extravasation 
results in T1 shortening, opposing the susceptibility contrast induced T2* relaxation rate 
change from intravascular GBCA that forms the basis for CBV estimation. Because GBCA 
is excluded from cells, GBCA extravasation establishes a magnetic susceptibility gradient 
not only between the intra- and extra-vascular spaces, but also between the intra- and 
extra-cellular spaces when sufficient GBCA distributes throughout the extravascular-
extracellular space, potentially exaggerating T2* changes. (As an example see Figure 5 
of Ref. [42] where in the same voxel the post-bolus signal can overshoot or undershoot 
baseline depending upon the accumulated dose of GBCA.) DSC-MRI signal is thereby 
affected not only by vascular volume fraction and vessel size, but also by the rate of 
GBCA extravasation (vascular permeability) and the cell volume fraction, cell size and 
cell distribution.28  Signal-time (and R2*-time) curves no longer return to baseline as they 
do for ideal tracer kinetics, but extend below or above baseline depending on whether T1 
or T2* effects dominate, thereby affecting the accuracy of CBV estimates determined from 
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the area under the R2*-time curve.43 The magnitude of this effect depends upon a 
combination of both DSC-MRI acquisition parameters and contrast agent dosing.42   
Methods for minimizing DSC-MRI signal contamination from GBCA extravasation 
include low FA pulse sequences that reduce T1 sensitivity;44 loading doses or “preload” 
contrast administration;5,8,45 and post-processing techniques including model-based 
leakage correction that can rectify both T1 and T2* leakage effects.5,8,45-47  Dual-echo 
DSC-MRI utilizes two GRE acquisitions with different TEs to estimate change in relaxation 
rate directly, thereby eliminating T1 contamination effects entirely, but still requires 
correction for T2* leakage effects48 and special pulse sequences that are less widely 
available.38,49 No technique has been universally accepted, and much of the debate about 
best DSC-MRI methodology centers on issues related to minimizing contamination of the 
DSC-MRI signal due to GBCA extravasation and maximizing CBV accuracy.  
Intravascular contrast agents like ferumoxytol eliminate contrast agent leakage 
effects entirely, and there is compelling evidence that ferumoxytol-based CBV 
measurements are inherently more accurate and precise than gadolinium-based CBV 
measurements because complications related to GBCA extravasation are minimized.50  
However, clinical application of ferumoxytol-based DSC-MRI may be limited. FDA-
approved as a therapeutic iron supplement, ferumoxytol is less commonly available than 
GBCA for MRI. GBCAs are widely accepted by radiologists for conventional post-contrast 
imaging and adding a second contrast agent for DSC-MRI would be logistically 
challenging. Although conventional contrast-enhanced imaging is feasible with 
ferumoxytol, it is practically performed 24 hours after agent administration.51  
Furthermore, the standardized BTIP requires post-contrast imaging after one total dose 
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of GBCA.30 Finally, gadolinium-based DSC-MRI permits measurement of additional 
physiological parameters related to GBCA extravasation, such as PSR (percent signal 
recovery of the signal-time curve compared to baseline), as well as Ktrans (volume transfer 
coefficient of gadolinium from the intravascular to the extravascular, extracellular space). 
Therefore, we focus on single-GRE GBCA-based DSC-MRI and the selection of four 
fundamental protocol choices: preload and bolus contrast agent dose, FA, TE, and post-
processing leakage correction.  
Preload Contrast Agent Dosing 
A “preload” dose of GBCA administered prior to the bolus dose of GBCA given 
during dynamic imaging can help mitigate T1 contamination. The preload dose partially 
saturates baseline T1-weighted signal contribution,5,8,45 thereby diminishing T1-induced 
increased signal during bolus passage. Evidence supporting preload administration 
includes data in a C6 rat glioma model, where (at least for high-FA acquisitions) there is 
no discernable DSC-MRI signal after the first (no preload) injection, and a “usable” DSC-
MRI signal for computing CBV with the second injection.46 A study comparing several 
different approaches for acquiring and computing rCBV maps in patients demonstrated 
that without preload, high-grade tumor may mistakenly show no rCBV elevation compared 
to normal brain, but expected rCBV elevation is found when a preload was used.42 
Preload dosing has varied in the literature, ranging from fractional doses up to a full 
equivalent dose. In a study using a 60° FA and post-processing leakage correction, Hu et 
al. found that a full-dose preload of 0.1 mmol/kg and an incubation time of 6 minutes 
between preload administration and bolus injection optimized the separation of CBVs for 
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tumor and treatment effect in HGGs with recurrent enhancement after standard 
chemoradiation.52  
Post-Processing Leakage Correction 
In practice, DSC-MRI acquisition cannot be decoupled from post-processing, and 
there is ample evidence that post-processing leakage-correction of DSC-MRI data is 
necessary for accurate rCBV measurement when the BBB is disrupted.5,8,45  A 
pharmacokinetic model-based approach described by Weisskoff et al.53 was the first 
published method for correcting T1-based GBCA leakage effects using a linear least-
squares fit of the R2*-time curves within the tumor and a reference region in non-
enhancing brain to correct the entire R2*-time curve, including first pass.5,8,45,46  The 
method was subsequently modified to correct T2* leakage effects as well,45,54 and it was 
empirically determined that the algorithm performed best with the collection of 120 time 
points, a finding consistent with the assumption of no contrast agent backflux. This 
leakage correction method is now sometimes referred to as the BSW method (after the 
authors of the subsequent paper that focused exclusively on the leakage correction 
algorithm8).   
Modifications to the BSW approach have since been published, including 
calculation of the tissue residue function allowing for a voxel-wise correction of the raw 
DSC-MRI signal that is insensitive to variations in MTT.46 The ability to determine 
additional perfusion parameters directly from the residue function has also been 
demonstrated.54 Most recently, a “bidirectional” version of the BSW method was 
developed that accounts for backflux of contrast agent,47,55 which becomes important with 
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the collection of >120 time points.  While other leakage correction methods like gamma-
variate fitting and post-bolus baseline correction have been used, studies suggest that 
these do not perform as well because they do not correct for leakage effects occurring 
throughout the DSC bolus.42,46  
Preload and model-based post-processing leakage correction are synergistic in 
their improvement of rCBV accuracy,42 and consensus recommendations for leakage-
corrected, single-echo DSC-MRI have been directed towards a technique combining the 
two methods.56  For high FA, rCBV using preload plus leakage correction strongly 
correlates with tumor grade, whereas uncorrected rCBV does not,8 and in a rat 
gliosarcoma model, combined preload and post-processing leakage correction yield CBV 
estimates that converge to gold standard values obtained using MION, an intravascular 
contrast agent.57  RCBV measurements using preload and the BSW method agree well 
with histology in spatially correlated tissue biopsies,58,59 and the BSW method has been 
applied in single-institution studies and multi-site clinical trials demonstrating, among 
other benefits, the utility of rCBV for predicting or detecting early responses to 
therapy.20,23,60,61  Nonetheless, there are potentially important improvements to be gained 
using modified BSW approaches that have yet to be thoroughly evaluated.   
Although the BSW method has been implemented by several commercial software 
vendors, discrepancies in computed rCBV arise in head-to-head comparisons,62 and 
caution is recommended for cross-platform comparisons. For instance, significantly 
different performance was observed when identical DSC-MRI data were processed with 
two software packages using different implementations of post-processing leakage 
correction.62 The best correlation of CBV with histology required preload plus post-
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processing leakage correction, providing evidence that leakage correction is important 
but that technique and implementation matter.  Marked inter-site disagreement has also 
been observed when site-specific software was applied to DSC-MRI data generated by a 
digital reference object (DRO) using a standardized imaging protocol.63 Nonetheless, it 
has been shown that when a single data set is carefully pre-processed eliminating 
differences in intermediate analysis steps (such as ROI selection and registration), then 
rCBV values computed by multiple sites using different platforms begin to converge,64 
and a “consensus” threshold is reached for distinguishing low-grade from high-grade 
gliomas. Therefore, implementation matters, motivating efforts to build consensus 
regarding post-processing and to establish a benchmark for validating DSC-MRI analysis 
tools, such as the DRO described below.65,66 
Impact of Flip Angle and TE 
For single-echo DSC-MRI, low to intermediate FA (i.e. 35°–60°) with longer TR 
(i.e. 1.2–1.7s) and TE (i.e. >20ms) can reduce T1 contamination due to GBCA 
extravasation.44 However, some parameter combinations may also reduce the SNR of 
the computed rCBV maps,67 and the goal is to minimize leakage effects while maintaining 
SNR.  Accordingly, there are high- and low-FA DSC-MRI strategies with tradeoffs, as 
summarized in Table 1. Acquisitions using low FA,44 long TE,68 and long TR69 have 
decreased T1 sensitivity, and less need for preload, but poorer CBV SNR. Higher FA,8 
shorter TE,70 and shorter TR67 may require preload to decrease T1 sensitivity, but have 
higher CBV SNR. 
We have direct validation of CBV accuracy using two different acquisition 
strategies. Stereotactic biopsies co-registered to leakage-corrected CBV maps made with 
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preload, 60° FA, and post-processing leakage correction have shown excellent 
correlation of CBV with histologic vascular area and density.58 Similarly, stereotactic 
biopsies co-registered to CBV maps made using no preload, a low FA (35°), and no 
model-based leakage correction also had good correlation of CBV with microvascular 
expression.71 The literature is replete with conflicting acquisition strategies such as these. 
Motivation for Standardization of DSC-MRI Methodology 
The application of DSC-MRI to treatment response assessment of HGGs 
illustrates the importance of harmonization of DSC-MRI methodology. There has been 
much investigation of the use of CBV for differentiating true tumor from treatment effects. 
Relative CBV has putative value for differentiating progressive disease (PD) 
characterized by enlarged microvessels with high vascular density from treatment effects 
characterized by inflammatory or steroid-like behavior as in pseudoprogression (PsP) or 
pseudoresponse, respectively.72-74  
CBV has been used to distinguish PsP and PD at initial progressive contrast 
enhancement after chemoradiation but the literature is somewhat conflicting. For 
instance, Prager et al. studied 68 HGGs at progressive enhancement and found 
significant difference in median rCBV between PsP and PD, with an optimal threshold of 
1.3.75 Other studies also found mean or median CBV to be predictive, with varying 
thresholds,19,76 but others have found mean CBV to be non-predictive or only predictive 
with qualification. Although Kong et al. found overall significant difference in mean rCBV 
between PsP and PD, this difference applied to GBMs with unmethylated but not with 
methylated MGMT.77  However, a study of HGGs treated with PPX, a powerful radiation 
sensitizer with a high incidence of PsP often coincident with PD, found no significant 
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difference in mean rCBV between PsP and PD at initial progressive enhancement.78 
These are just a few examples of varied results in the literature. 
Variability of DSC-MRI Methodology in the Literature 
Literature results may conflict at least in part because DSC-MRI methodology 
varies greatly. Patel et al. published a meta-analysis of 17 studies where DSC-MRI was 
used to differentiate recurrent HGG from treatment-related enhancement.79  For the 
subgroup of studies using mean lesion rCBV, they found “relatively good accuracy in 
individual studies” with high pooled sensitivity (88% [0.81-0.94]) and specificity (88% 
[0.78-0.95]) for recurrent tumor, but there was a wide range of optimal mean CBV 
thresholds (0.9–2.15). This variation has been attributed to the wide range of TR, TE, FA, 
preload dose and post-processing leakage correction used by these studies, as 
summarized in Figure 1. Variable parameters are also found in subsequent literature.  For 
instance, using spatially correlated histologic tissue samples, TR = 1100-1250ms, 
TE = 30ms, FA = 70-80°, ½-1 dose preload with full-dose bolus, and post-processing 
leakage correction (IB Neuro), Prah et al. found a nRCBV cutoff of 1.13 with 82% 
sensitivity and 90% specificity.59 Patel et al. concluded that “because of significant 
variability in optimal reported thresholds…further investigation and standardization is 
needed before implementing any particular quantitative PWI strategy across institutions.” 
On a similar note, Quarles et al. organized a Quantitative Imaging Network (QIN) 
DSC-MRI challenge with 12 NCI-QIN centers to explore factors related to CBV 
consistency.63 They simulated a 10,000-voxel population-based DRO for each site’s 
DSC-MRI protocol (19 total protocols),65 and used corresponding DSC-MRI signal curves 
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for three evaluations of inter-site CBV consistency: central processing of CBV for site-
specific DROs (isolated impact of acquisition protocol); site-specific processing of CBV 
for standard DRO (isolated impact of post-processing methodology); and site-specific 
processing of CBV for site-specific DROs (combined impact of acquisition and post-
processing). The 3T DSC-MRI acquisition protocol varied considerably for the 12 sites 
(15 paradigms). Though TR and TE were relatively consistent (possibly reflecting 
adoption of previously published protocol recommendations56), FA and preload dosing 
varied considerably, with a wide gamut of post-processing methodology, including 
software, integration limits, and normalization to white matter. When local sites chose 
both acquisition and post-processing, there was very poor cross-site intra-class 
correlation for CBV, particularly for simulated blood-brain barrier disruption typical for 
GBMs, and with large limits of agreement on Bland-Altman analysis. There was better 
correlation when acquisition or post-processing was standardized, especially post-
processing. Overall, this study demonstrates that CBV variability can arise from 
differences in post-processing as well as image acquisition. This has profound 
implications for comparing literature CBV values from sites using dissimilar acquisition 
and post-processing schemes. For clinical trials, although acquisition and post-
processing methods are typically standardized, the most accurate and proven 
approaches should be used for determining the therapeutic effectiveness of a drug, or 
establishing thresholds for categorical response (e.g., predetermined changes in CBV 
used to refine RANO criteria). 
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Previous Efforts at Standardization: ASFNR White Paper (2015) 
Efforts at standardization have been made by several organizations including the 
ASFNR, which published a white paper with the following recommendations: single-echo, 
GRE pulse sequence; TR = 1.0-1.5s; TE = 40-45ms at 1.5T, 25-35ms at 3T; FA = 60-70°; 
acquisition duration of at least 120 total time points, including at least 30-50 baseline 
acquisitions; and ¼-1 dose preload with full-dose bolus.56  These recommendations were 
made prior to the publication of the standardized BTIP,30 which is gaining clinical 
acceptance. 
BTIP Compliance and Implication for Allowable Dosing Schemes 
It is sensible that a standardized DSC-MRI protocol be compatible with BTIP. BTIP 
mandates that conventional post-contrast T1-weighted imaging be performed after one 
full dose of GBCA, either split between preload and DSC-MRI bolus before post-contrast 
imaging, or fully given as preload with variable bolus dose DSC-MRI after post-contrast 
imaging. This sets constraints on the range of preload and bolus doses that should be 
considered for inclusion in a universal DSC-MRI protocol. Possible BTIP-compliant DSC-
MRI preload and bolus paradigms are illustrated in Figure 2. 
Selection of Optimal DSC-MRI Parameters: Computational Approach 
Because it is impractical to compare all possible acquisition schemes in vivo, 




Using a multi-compartment model-based simulation of DSC-MRI signal derived 
from convolution theory,80 the theoretical framework developed by Quarles et al.,43 and 
characteristics from 250 randomly chosen tumors, Leu et al. systematically evaluated the 
effects of various acquisition and post-processing leakage correction strategies, including 
a range of FA, TE, and TR with BTIP-compliant contrast agent dosing schemes, on the 
fidelity of CBV estimation in the presence of Gaussian noise.81 Results of this 
comprehensive study are summarized in Figure 3. Although no single acquisition scheme 
was absolutely optimal, several parameter combinations yielded the lowest error in CBV 
estimation. The best performing acquisition schemes included 60° FA with full-dose 
preload and full-dose bolus (“1+1” double-dose GBCA), as well as 35° FA without preload. 
Importantly, high-FA acquisitions with no or fractional preload dosing performed relatively 
poorly.  
Similarly, Semmineh et al. used a validated population-based DRO, derived from 
3D tumor tissue microstructures and trained on 23 DSC-MRI glioblastoma datasets 
including more than 40,000 voxels.65 They simulated tumor CBV acquired with BTIP-
compliant dosing schemes, and a similar range of FA, TE, and TR. Simulated CBV without 
leakage was the reference standard, and they evaluated concordance correlation 
coefficient and coefficient of variation as measures of accuracy and precision, 
respectively. They produced heat maps with similar findings as Leu et al. The best 
performing schemes used full-dose preload and full-dose bolus at low to intermediate FA, 
with poor performance for intermediate-high FAs using no or fractional preload, 
particularly at 1.5 T.66 Confluent regions of high performance are desirable because these 
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schemes would presumably be less sensitive to minor parameter variations or to 
underlying model assumptions or tumor physiology. 
Figure 4 summarizes performance of the intermediate 60° FA scheme from the 
ASFNR white paper versus a high-performing, low FA scheme for TR=1.5s.  Full-dose 
preload with full-dose bolus (“1+1” double-dose GBCA) provides the highest accuracy 
and precision for both schemes with similar performance at 1.5 and 3T.  With intermediate 
FA, single total dose schemes have poorer performance, especially at 1.5T, with 
moderate performance for split dose at 3T. Low FA acquisitions give much better 
performance for single total dose. For single-dose contrast without preload, the ASFNR 
parameters (i.e., intermediate FA) perform poorly, but low FA maintains excellent 
performance, even at 1.5T. Non-BTIP compliant preload dosing (e.g., ½ or ¼ dose) with 
full-dose bolus can give excellent results with low FA and intermediate FA at 3T, and very 
good results at 1.5T. 
Convergence of results from these simulations suggest that even without preload 
(i.e., “0+1” dosing), a low FA scheme gives very accurate CBV with much less bias 
compared to intermediate FA, even at 1.5T, and could be an attractive approach requiring 
less contrast agent (Figure 5A). 
With the application of simultaneous multi-slice or multi-band techniques, it is 
possible to shorten the temporal resolution to sub-second TRs, while maintaining 
sufficient spatial coverage. DRO-based recommendations for TR, TE, and FA seek the 
optimal T1 and T2* sensitivity, and sub-second TRs will increase sensitivity to T1 leakage 
effects and reduce rCBV fidelity. For example, the DRO analysis for “0+1” dosing and the 
optimal low FA approach described above (30° FA, 30ms TE) predicts that the 
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concordance correlation coefficient (CCC), a measure of CBV accuracy, drops to 0.76 
and 0.62 for TR=750ms and 500ms, respectively. Even if TE is increased to 50ms, CBV 
accuracy is lower (CCC<0.9) than that achieved using more conventional TRs (1–1.5s). 
However, for “1+1” dosing and the optimal low FA scheme, the CCC exceeds 0.95, even 
for TRs as low as 500ms. These results highlight the importance of parameter 
consistency and encourage caution when applying acceleration techniques. 
In vivo Assessment of Low FA, No Preload DSC-MRI 
A recent study was performed to validate in vivo the simulations predicting that 
single-dose, low-FA DSC-MRI acquisitions without preload (“0+1” dosing) give rCBV 
estimates practically equivalent to the double-dose, intermediate-FA reference standard 
using full-dose preload (“1+1” dosing).82  84 patients with a contrast-enhancing brain 
lesion were included in this four-institution study.  As shown in Figure 5B, the study 
demonstrated practical equivalence between the two methods, supporting the idea that 
this low-dose approach should be considered for consensus protocol recommendation, 
at least at 3T.  The agreement between the two methods was poor if post-processing 
leakage correction (BSW method) was not also applied. Confirmation of equivalence at 
1.5T requires a similar study. 
Conclusions from Computational Parameter Analyses and In Vivo 
Comparison Study 
Based on the recent literature, the following conclusions can be drawn regarding 
DSC-MRI acquisition methodology: 
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1) Of the BTIP-compliant dosing schemes investigated, full-dose preload with full-dose 
bolus (“1+1” dosing) has superior performance, with the least sensitivity to minor pulse 
sequence parameter fluctuations and the best combination of accuracy and precision, 
which is important for clinical trials that aim to minimize sample size. Although both low 
FA (30°) and intermediate FA (60°) sequences provide a high degree of accuracy in 
simulations testing the “1+1” dosing scheme, we continue to consider intermediate FA 
(60°) to be the gold standard for “1+1” dosing, particularly at 3T field strength, given the 
benefits of higher CNR and lower sensitivity to parameter variations (e.g., TE, TR) 
compared to low FA (30°) acquisitions. 
2) When the “1+1” dosing scheme is not desirable (e.g., when prioritizing low GBCA 
dosage), the no-preload paradigm (“0+1” dosing) with low FA (30°) and an optimally 
selected and field-strength dependent TE provides an excellent practical alternative to 
the gold standard and is the recommended alternative method, particularly at 3T for which 
in vivo validation has been performed.  Based on simulation testing of the “0+1” dosing 
scheme, low FA (30°) acquisitions provide superior accuracy and precision compared to 
the intermediate FA (60°).  This appears to hold true at both 1.5T and 3T field strengths 
(though has not yet been validated in vivo at 1.5T).  
3) For both the “1+1” dosing at intermediate FA (60°) and “0+1” dosing at low FA (30°), 
there is a modest theoretical performance advantage at 3T versus 1.5T. 
4) For BTIP-compliant fractional dosing (e.g., “½+½”and “¼+¾” dosing schemes), a low 
FA (30°) acquisition should be used at all field strengths, given the superior accuracy and 
precision compared to intermediate FA (60°) acquisitions, with TE = 30-50ms having 
theoretical advantages, especially at 1.5T.  However, these fractional dosing schemes 
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likely have poorer performance than the “0+1” dosing scheme and the gold-standard 
“1+1” dosing scheme, due to the theoretical costs of poor CNR for fractional bolus dosing, 
particularly for perfusion metrics such as cerebral blood flow CBF and MTT.    
5) Post-processing leakage correction is always beneficial, even for low FA (30°) 
acquisitions, and should be utilized in routine practice.  
Time-point specifications 
Number of baseline time points 
Because the number of baseline acquisitions impacts CBV map SNR, image 
acquisition should begin at least 30–50 time points before contrast injection via a power 
injector.67 
Number of post-bolus time points 
Post-processing leakage-correction algorithms and PSR analysis utilize post-bolus 
“tail” signal intensities, necessitating acquisition of sufficient post-bolus time points. 120 
total time points (for a typical TR of 1.0–1.5s) have been shown by simulation to yield 
optimal results using the BSW post-processing leakage correction methodology and a 
30-50 time point baseline.66  For longer total acquisitions (e.g., 180 time points), reflux of 
contrast agent back into blood vessels is more likely to occur, violating assumptions of 
unidirectional contrast agent efflux.8  In such cases, bidirectional contrast agent leakage 
correction schemes are more accurate,47 with similar accuracy for unidirectional and 
bidirectional leakage correction when 120 total time points are acquired.66 
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Compatibility with DCE-MRI 
When acquisition of both DCE- and DSC-MRI is desired for a single exam, DCE-
MRI is typically performed using the preload dose for DSC-MRI. Preload-based, BTIP-
compliant dosing strategies that have been previously evaluated include the “1+1” and 
“½+½” protocols.  Due to the higher CNR of full-dose acquisitions, the “1+1” dosing 
scheme provides superior DCE- and DSC-parameter accuracy and precision. However, 
as highlighted in Figure 4, the “½+½” protocol with low FA (30°) provides a reasonable 
alternative with a modest reduction in accuracy and precision. It is important to note that 
although the DSC-MRI preload could be used for DCE-MRI, dosage needs to be guided 
by both DCE-MRI requirements and BTIP compliance, and further investigation is 
required for determining the fidelity and clinical utility for candidate dosing strategies.  
Summary of Updated Recommendations for DSC-MRI Parameters 
In light of the emergence of the BTIP standards,30 recent computer simulation 
results,66,81 and multi-site in vivo validation,82 our committee is proposing several 
modifications to the previously published ASFNR recommendations. Because adoption 
of DSC-MRI is anticipated for multi-site trials, our modified DSC-MRI protocol is BTIP-
compliant, imposing constraints on contrast agent preload and bolus selection. 
From a theoretical perspective, a full-dose preload, full-dose bolus dosing scheme 
(“1+1”), using low (30°) or intermediate (60°) FA and field strength-dependent TE (40-
50ms at 1.5T, 25-35ms at 3T) provides overall best performance based upon accuracy 
and precision estimates. In clinical trials or at independent clinical sites where double 
contrast agent dose is acceptable and highest performance is desired, the double-dose 
 N-O-D-20-00183R1 
 27 
(“1+1”) approach can be used. However, when single-dose GBCA usage is desired or 
required, we recommend a no-preload, full-dose bolus dosing scheme (“0+1”) using low 
FA (30°) and field strength-dependent TE (40-50ms at 1.5T, 25-35ms at 3T). For most 
typical applications and with excellent performance preservation, the “0+1” approach has 
advantages, including reduced GBCA usage, as well as elimination of potential 
systematic error introduced by variation in incubation time between preload and bolus 
administrations. Although the no-preload, low-FA scheme has slightly poorer accuracy 
and precision than the full-dose preload, full-dose bolus scheme, the “1+1” scheme uses 
more GBCA, and that downside may more than outweigh the slight gain in performance. 
Even the fractional dosing schemes (“¼+¾” and “½+½”), with near equivalent 
performance using low FA, still have the disadvantage of requiring preload, and potential 
variation in incubation times can lead to systematic errors. Therefore, the no-preload 
“0+1” protocol may be most appropriate for routine clinical use.   
Post-processing leakage correction is beneficial, even for low FA (30°) 
acquisitions, and should be utilized in routine practice. The BSW method is an advisable 
technique for performing post-processing model-based leakage correction and has thus 
far the most computer simulation and clinical evidence to support its utility. In the absence 
of universal acceptance of a single software implementation for widespread use, a 
benchmark may be required for validating independent DSC-MRI post-processing tools, 
such as the DRO methodology referenced above. 
The updated DSC-MRI protocol recommendations are summarized in Table 2.  
Integrated BTIP and DSC-MRI protocols for the “0+1” and “1+1” dosing schemes are 
summarized in Supplemental Table 1 and Table 2, respectively.  
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As a final thought, it is worth noting that although the updated DSC-MRI protocol 
is motivated by theory, computer simulations, in vivo studies, and clinical trial data related 
to high-grade gliomas, the principles apply to any contrast-enhancing brain lesion, 
including metastases and active inflammation or infection. Therefore, we believe that the 
protocol recommendations herein are generally applicable to routine clinical practice. 
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Figure 1.  
DSC-MRI methodology in the literature varies greatly, as seen in the subgroup meta-
analysis by Patel et al. of studies using mean lesion rCBV for recurrent high-grade tumor 
vs. treatment effect. These studies used a wide range of DSC-MRI parameters including 
TE, FA, preload dose and post-processing leakage correction (PPLC). (Adapted from Ref. 
[79].)  
Figure 2.  
Possible BTIP-compliant DSC-MRI preload + bolus dose paradigms. Either a single total 
dose must be split between preload and DSC-MRI before post-GBCA imaging, or a full 
dose preload must be given with DSC-MRI after post-contrast imaging. 
Figure 3.  
Computational approach for determining optimal BTIP-compliant DSC-MRI parameters 
using simulated DSC-MRI signal with GBCA leakage: heat maps of CBV error versus 
theoretical CBV without leakage for different combinations of acquisition parameters. 
Schemes with particularly high fidelity at 3T include 60° FA with full-dose preload and 
bolus (asterisk with dashed box) and low FA without preload (asterisk with solid box). 
(Adapted from Ref. [81].) 
Figure 4.  
Computational approach for determining optimal BTIP-compliant DSC-MRI parameters 
using a digital reference object matched to glioblastoma training data: performance 
comparison for intermediate and low flip angle schemes. For double-dose contrast with 
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full-dose preload, both schemes have excellent accuracy and precision at 1.5T and 3T. 
For single-dose contrast without preload, intermediate FA performs poorly but low FA 
maintains excellent performance, even at 1.5T. For each dosing scheme, low FA had 
equal or better performance than intermediate FA. CCC = Concordance correlation 
coefficient (accuracy); CV = coefficient of variation (precision). (Adapted from Ref. [66].) 
Figure 5.  
A) DRO-based simulations demonstrate that even without preload, low FA (30°) 
acquisitions give very accurate CBV (along the line of unity) with much less bias 
compared to intermediate FA (60°) acquisitions, even at 1.5T. (Adapted from Ref. [66].) 
B) Excellent CBV agreement has been observed in vivo at 3T for “0+1” and “1+1” dosing 
schemes, according to Lin’s concordance correlation (CCC). 




Parameter CBV SNR T1 sensitivity Reference 
Flip angle    
Low Decrease Decrease Cha et al. 
Radiology 200244 
High Increase Increase Boxerman et al. 
AJNR 20068 
TE    
Long Decrease Decrease Thilmann Et al. 
MRI 200468 
Short Increase Increase Smith et al. 
MRM 200370 
TR    
Long Decrease Decrease Knutsson et al. 
MRI 200469 
Short Increase Increase Boxerman et al. 
JMRI 199767 
Preload contrast agent administration 
Pros Cons Reference 
Decreased T1 sensitivity Extra contrast agent Donahue et al. 
MRM 20005 





Table 2: Summary of protocol recommendations for BTIP-compliant DSC-MRI 
Parameter 3T Recommendations (Range) 1.5T Recommendations (Range) 
Pulse sequence GRE-EPI 
Plane Axial (Oblique Axial) 
Mode 2D 
Dosing protocol 
(preload + bolus) 
“1 + 1”: Optimal performance (Preload  T1w+C  DSC bolus injection)  
“0 + 1”: Optimal for single total dose (DSC bolus injection  T1w+C) 
Repetition Time (TR) 
(msec) 
1000-1500 
Echo Time (TE)  
(msec) 
30 (25 – 35) for 30° FA 
30 (20 – 35) for 60° FA 
45 (40 – 50) 
Flip Angle (FA)  
(deg) 
60 (60-65) or 30 (30-35) (“1 + 1” dosing) 
30 (30-35) (“0 + 1” dosing) 
Total time points ≥ 120 
Baseline time points 50 (30 – 50) 
Field of view (mm) (220 – 240) 
Acquisition matrix 128 x 128 (96-128 x 96-128) ≥ 96 x 96 (96-128 x 96-128) 
Slice thickness (mm) 3 (3-5),  
as needed for tumor coverage 
4 (4-5),  
as needed for tumor coverage 
Slice gap (mm) 0 (0 – 1), as needed for tumor coverage 
Parallel imaging 
(GRAPPA/SENSE/CAIPI) 
≤ 2x  
Post-processing leakage 
correction 
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Supplemental TABLE 1: “0+1” 1.5T & 3T MRI PROTOCOL 
 
 3D T1w Preb Ax 2D 
FLAIRf 
Ax 2D DWI Ax 2D T2we DSC-MRIa 3D T1w Postb 
Sequence IR-GREd TSEc EPI TSEc GRE EPI IR-GREd 
Plane Sagittal/Axial Axial Axial Axial Axial Sagittal/Axial 
Mode 3D 2D 2D 2D 2D 3D 
TR [ms] 2100k >6000 >5000 >2500 1000-1500 2100k 
TE [ms] Min 100-140 Min 80-120 3T: 30 (25-35) 
1.5T: 45 (40-50) 
Min 
TI [ms] 1100j 2000-2500g    1100j 
Flip Angle [º] 10-15 90/160 90/180 90/160 30 (30-35) 10-15 
Frequency 256 256 128 256 128 (96-128) 256 
Phase 256 256 128 256 128 (96-128) 256 
NEX 1 1 1 1 1 1 
FOV [mm] 256 240 240 240 220-240 256 
Slice Thickness [mm] 1 4h 4h 4h 3-5i 1 
Gap/Spacing [mm] 0 0 0 0 0i 0 
Diffusion Optionsl   b = 0, 500, 
1000 s/mm2 
3 directions 
   
Perfusion Timepoints     50 (30-50) baseline, 
120 total 
 
Parallel Imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x 
Scan Time 
(Approx) 
[Benchmarked on 3T 
Skyra] 
5-10 min 
[5:49 for 1mm 
isotropic] 
4-8 min 
[3:22 for 2D 
FLAIR] 
2-4 min 




4-8 min 2-3 min 5-10 min 
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a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector at an injection rate of 3-5cc/sec. Maximize slice coverage to 
include the entire lesion as well as normal brain to the skull vertex.  The posterior fossa can be excluded from coverage if there are not enough slices to cover the 
entire brain. 
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) and 
the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast 
field echo (3D Fast FE; Toshiba). A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 
3D T1-weighted sequences and therefore should be avoided. 
e Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, PD is recommended to have a TE < 25ms. 
f 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC guidelines: 3D TSE/FSE acquisition; TE=90-140ms; 
TR=6000-10000ms; TI=2000-2500ms (chosen based on vendor recommendations for optimized protocol and field strength); GRAPPA2; Fat Saturation; Slice 
thickness  1.5mm; Orientation Sagittal or Axial; FOV  250 mm x 250 mm; Matrix  244x244. 
g Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI  2000ms for 1.5T and TI  2500ms for 3T). 
h In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) images with 5mm slice thickness or increase NEX for slice 
thickness 4mm. 
i Slice thickness and inter-slice gap can be adjusted as needed for tumor coverage. 
j For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast.  
k For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast. 
l Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three dimensional; 
TSE = turbo spin echo; EPI = echo planar imaging; SS-EPI = single-shot echo planar imaging; GRE EPI = gradient echo echo planar imaging; 
MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; NEX = number of excitations or averages; FOV = field of 




Supplemental TABLE 2: “1+1” 1.5T & 3T MRI PROTOCOL 
 
 3D T1w Preb Ax 2D 
FLAIRf 




















Ax 2D T2we 3D T1w Postb DSC-MRIm 
Sequence IR-GREd TSEc EPI TSEc IR-GREd GRE-EPI 
Plane Sagittal/Axial Axial Axial Axial Axial/Sagittal Axial 
Mode 3D 2D 2D 2D 3D 2D 
TR [ms] 2100k >6000 >5000 >2500 2100k 1000-1500 
TE [ms] Min 100-140 Min 80-120 Min 3T: 30 (20-35) 
1.5T: 45 (40-50) 
TI [ms] 1100j 2000-2500g   1100j  
Flip Angle [º] 10-15 90/160 90/180 90/160 10-15 60 (60-65) 
Frequency 256 256 128 256 256 128 (96-128) 
Phase 256 256 128 256 256 128 (96-128) 
NEX 1 1 1 1 1 1 
FOV [mm] 256 240 240 240 256 220-240 
Slice Thickness [mm] 1 4h 4h 4h 1 3-5i 
Gap/Spacing [mm] 0 0 0 0 0 0 
Diffusion Optionsl   b = 0, 500, 
1000 s/mm2 
3 directions 
   
Perfusion Timepoints      50 (30-50) baseline, 
120 total 
Parallel Imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x 
Scan Time 
(Approx) 
[Benchmarked on 3T 
Skyra] 
5-10 min 
[5:49 for 1mm 
isotropic] 
4-8 min 
[3:22 for 2D 
FLAIR] 
2-4 min 




4-8 min 5-10 min 
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a 0.10 mmol/kg (1 dose) preload should be injected 1-2 minutes prior to DSC-MRI acquisition.  
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = magnetization prepared rapid gradient-echo (Siemens 
& Hitachi) and the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo 
(TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba). A 3D acquisition without inversion preparation will result in different contrast compared 
with MPRAGE or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
e Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, PD is recommended to have a TE < 25ms. 
f 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC guidelines: 3D TSE/FSE acquisition; 
TE=90-140ms; TR=6000-10000ms; TI=2000-2500ms (chosen based on vendor recommendations for optimized protocol and field strength); 
GRAPPA2; Fat Saturation; Slice thickness  1.5mm; Orientation Sagittal or Axial; FOV  250 mm x 250 mm; Matrix  244x244. 
g Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI  2000ms for 1.5T and TI  2500ms for 3T). 
h In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) images with 5mm slice thickness or increase 
NEX for slice thickness 4mm. 
i Slice thickness and inter-slice gap can be adjusted as needed for tumor coverage. 
j For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast.  
k For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast. 
l Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
m 0.1 mmol/kg (1 dose) injection with a Gadolinium chelated contrast agent. Use of a power injector at an injection rate of 3-5cc/sec. Maximize slice 
coverage to include the entire lesion as well as normal brain to the skull vertex.  The posterior fossa can be excluded from coverage if there are not 
enough slices to cover the entire brain. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three 
dimensional; TSE = turbo spin echo; EPI = echo planar imaging; SS-EPI = single-shot echo planar imaging; GRE EPI = gradient echo echo planar 
imaging; MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; NEX = number of excitations or 
averages; FOV = field of view; TE = echo time; TR = repetition time; TI = inversion time; PD = proton density; DSC = dynamic susceptibility 
contrast; IR-GRE = inversion-recovery gradient-recalled echo 
 
 
